bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
Authors: Xu Junfeng , Ye Zeng , Zhuo Qifeng , Gao Heli , Qin Yi , Lou Xin , Zhang Wuhu , Wang Fei , Wang Yan , Jing Desheng , Fan Guixiong , Zhang Yue , Chen Xuemin , Chen Jie , Xu Xiaowu , Yu Xianjun , Ji Shunrong
Published: July 2023

Clinicopathologic parameters according to the expression of NAE1, Ubc12, Rbx1 and global NEDD8 conjugation
Figure S1 from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression
Authors: Xu Junfeng , Ye Zeng , Zhuo Qifeng , Gao Heli , Qin Yi , Lou Xin , Zhang Wuhu , Wang Fei , Wang Yan , Jing Desheng , Fan Guixiong , Zhang Yue , Chen Xuemin , Chen Jie , Xu Xiaowu , Yu Xianjun , Ji Shunrong
Published: July 2023

Representative tandem MS spectrum of the LPENYTDETWQK peptide from CUL4B as determined by IP-Mass Spec
Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
Authors: Cao Kankan , Zhang Guodong , Yang Moran , Wang Yiying , He Mengdi , Zhang Chen , Huang Yan , Lu Jiaqi , Liu Haiou
Published: July 2023

Materials and Methods: Supplementary Figure S1 to S14 for multiple supplementary figures
Supplementary Data from Attenuation of Sialylation Augments Antitumor Immunity and Improves Response to Immunotherapy in Ovarian Cancer
Authors: Cao Kankan , Zhang Guodong , Yang Moran , Wang Yiying , He Mengdi , Zhang Chen , Huang Yan , Lu Jiaqi , Liu Haiou
Published: July 2023

Supplementary Tables S1 to S9 for multiple supplementary tables
Supplementary Information from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Authors: Mohan Dipika R. , Borges Kleiton S. , Finco Isabella , LaPensee Christopher R. , Rege Juilee , Solon April L. , Little Donald W. , Else Tobias , Almeida Madson Q. , Dang Derek , Haggerty-Skeans James , Apfelbaum April A. , Vinco Michelle , Wakamatsu Alda , Mariani Beatriz M.P. , Amorim Larissa Costa , Latronico Ana Claudia , Mendonca Berenice B. , Zerbini Maria Claudia N. , Lawlor Elizabeth R. , Ohi Ryoma , Auchus Richard J. , Rainey William E. , Marie Suely K.N. , Giordano Thomas J. , Venneti Sriram , Fragoso Maria Candida Barisson Villares , Breault David T. , Lerario Antonio Marcondes , Hammer Gary D.
Published: July 2023

Supplementary Information:Supplementary Figures 1-6 with Figure Legends, Supplementary Table 1 (reference only), Supplementary Table 2, Supplementary Methods, Supplementary References
Supplementary Data from β-Catenin–Driven Differentiation Is a Tissue-Specific Epigenetic Vulnerability in Adrenal Cancer
Authors: Mohan Dipika R. , Borges Kleiton S. , Finco Isabella , LaPensee Christopher R. , Rege Juilee , Solon April L. , Little Donald W. , Else Tobias , Almeida Madson Q. , Dang Derek , Haggerty-Skeans James , Apfelbaum April A. , Vinco Michelle , Wakamatsu Alda , Mariani Beatriz M.P. , Amorim Larissa Costa , Latronico Ana Claudia , Mendonca Berenice B. , Zerbini Maria Claudia N. , Lawlor Elizabeth R. , Ohi Ryoma , Auchus Richard J. , Rainey William E. , Marie Suely K.N. , Giordano Thomas J. , Venneti Sriram , Fragoso Maria Candida Barisson Villares , Breault David T. , Lerario Antonio Marcondes , Hammer Gary D.
Published: July 2023

Supplementary Table 1: NCI-H295R RNA-seq FPKM table, Related to Figures 2-4, 6.
Data from N6-Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer
Authors: Zhang Haisheng , Zhou Jiawang , Li Jiexin , Wang Zhaotong , Chen Zhuojia , Lv Ziyan , Ge Lichen , Xie Guoyou , Deng Guoming , Rui Yalan , Huang Hongbing , Chen Likun , Wang Hongsheng
Published: July 2023

Abstract
Angiogenesis is hijacked by cancer to support tumor growth. RNA modifications such as N6-methyladenosine (m6A) can regulate several aspects of cancer, including angiogenesis. Here, we find that m6A triggers angiogenesis in lung cancer by upregulating VEGFA, a central regulator of neovasculature and blood vessel growth. m6A-sequencing and functional studies confirmed that m6A modification of the 5′UTR (untranslated region) of VEGFA positively regulates its translation. Specifically, methylation of a 5′UTR internal ribosome entry site (IRES) recruited the YTHDC2/eIF4GI complex to trigger cap-independent translation initiation. Intriguingly, the m6A methylation site A856 of the 5′UTR was located within the conserved upstream open reading frame (uORF) of VEGFA IRES-A, which overcomes uORF-mediated translation suppression while facilitating G-quadruplex–induced translation of VEGFA. Targeted specific demethylation of VEGFA m6A significantly decreased expression of VEGFA and reduced lung cancer cell–driven angiogenesis. In vivo and clinical data confirmed the positive effects of m6A modification of VEGFA on angiogenesis and tumor growth of lung cancer. This study not only reveals that the m6A/VEGFA axis is a potential target for lung cancer therapy but also expands our understanding of the impact of m6A modification of IRES in the 5′UTR of mRNA on translation regulation.
Significance:
Methylation of the 5′UTR IRES of VEGFA mRNA increases cap-independent translation via recruitment of the YTHDC2/eIF4GI complex, which stimulates angiogenesis to promote lung tumor growth.
Data from Metabolic Reprogramming Driven by IGF2BP3 Promotes Acquired Resistance to EGFR Inhibitors in Non–Small Cell Lung Cancer
Authors: Lin Ziyou , Li Jingwei , Zhang Jian , Feng Weineng , Lu Jiaye , Ma Xiaofan , Ding Wen , Ouyang Shumin , Lu Jinjian , Yue Peibin , Wan Guohui , Liu Peiqing , Zhang Xiaolei
Published: July 2023

Abstract
Acquired resistance represents a bottleneck for effective molecular targeted therapy in lung cancer. Metabolic adaptation is a distinct hallmark of human lung cancer that might contribute to acquired resistance. In this study, we discovered a novel mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) mediated by IGF2BP3-dependent cross-talk between epigenetic modifications and metabolic reprogramming through the IGF2BP3–COX6B2 axis. IGF2BP3 was upregulated in patients with TKI-resistant non–small cell lung cancer, and high IGF2BP3 expression correlated with reduced overall survival. Upregulated expression of the RNA binding protein IGF2BP3 in lung cancer cells reduced sensitivity to TKI treatment and exacerbated the development of drug resistance via promoting oxidative phosphorylation (OXPHOS). COX6B2 mRNA bound IGF2BP3, and COX6B2 was required for increased OXPHOS and acquired EGFR-TKI resistance mediated by IGF2BP3. Mechanistically, IGF2BP3 bound to the 3′-untranslated region of COX6B2 in an m6A-dependent manner to increase COX6B2 mRNA stability. Moreover, the IGF2BP3–COX6B2 axis regulated nicotinamide metabolism, which can alter OXPHOS and promote EGFR-TKI acquired resistance. Inhibition of OXPHOS with IACS-010759, a small-molecule inhibitor, resulted in strong growth suppression in vitro and in vivo in a gefitinib-resistant patient-derived xenograft model. Collectively, these findings suggest that metabolic reprogramming by the IGF2BP3–COX6B2 axis plays a critical role in TKI resistance and confers a targetable metabolic vulnerability to overcome acquired resistance to EGFR-TKIs in lung cancer.
Significance:
IGF2BP3 stabilizes COX6B2 to increase oxidative phosphorylation and to drive resistance to EGFR inhibitors in lung cancer, which provides a therapeutic strategy to overcome acquired resistance by targeting metabolic transitions.
Data from TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT–Smad3–SHP1 Axis in Lung Adenocarcinoma
Authors: Ye Fan , Cai Zihao , Wang Boyu , Zeng Chenxi , Xi Yu , Hu Shaojie , Qu Rirong , Yuan Zhiwei , Yue Jiaqi , Tian Yitao , Wang Xue , Fu Xiangning , Li Lequn
Published: July 2023

Abstract
IFNγ-mediated signaling in tumor cells can induce immunosuppressive responses and cause tumor resistance to immunotherapy. Blocking TGFβ promotes T lymphocyte infiltration and turns immunologically cold tumors into hot tumors, thereby improving the efficacy of immunotherapy. Several studies have shown that TGFβ inhibits IFNγ signaling in immune cells. We thus sought to determine whether TGFβ affects IFNγ signaling in tumor cells and plays a role in the development of acquired resistance to immunotherapy. TGFβ stimulation of tumor cells increased SHP1 phosphatase activity in an AKT–Smad3-dependent manner, decreased IFNγ-mediated tyrosine phosphorylation of JAK1/2 and STAT1, and suppressed the expression of STAT1-dependent immune evasion–related molecules, e.g., PD-L1, IDO1, herpes virus entry mediator (HVEM), and galectin-9 (Gal-9). In a lung cancer mouse model, dual blockade of TGFβ and PD-L1 led to superior antitumor activity and prolonged survival compared with anti–PD-L1 therapy alone. However, prolonged combined treatment resulted in tumor resistance to immunotherapy and increased expression of PD-L1, IDO1, HVEM, and Gal-9. Interestingly, after initial anti–PD-L1 monotherapy, dual TGFβ and PD-L1 blockade promoted both immune evasion gene expression and tumor growth compared with that in tumors treated with continuous PD-L1 monotherapy. Alternatively, treatment with JAK1/2 inhibitor following initial anti–PD-L1 therapy effectively suppressed tumor growth and downregulated immune evasion gene expression in tumors, indicating the involvement of IFNγ signaling in immunotherapy resistance development. These results demonstrate an unappreciated effect of TGFβ on the development of IFNγ-mediated tumor resistance to immunotherapy.
Significance:
Blocking TGFβ facilitates IFNγ-mediated resistance to anti–PD-L1 therapy due to the role of TGFβ in inhibiting IFNγ-induced immunoevasion by increasing SHP1 phosphatase activity in tumor cells.
Supplementary Table S1 from Tobacco Smoke Is a Major Source of Aromatic Amine Exposure in U.S. Adults: 2013–2014 National Health and Nutrition Examination Survey (NHANES)
Authors: Seyler Tiffany , Mazumder Shrila , Ahamed Rayaj , Zhu Wanzhe , Blount Benjamin C. , Apelberg Benjamin J. , Wang Lanqing
Published: July 2023

Supplementary Table S1: Details of USDA food codes and logic for apportioning dietary intake used in our analysis
Supplementary Table 8 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 8 includes one-year cumulative incidences for HCC surveillance overall and by insurance type, by calendar year of cirrhosis diagnosis (% and 95% confidence intervals).
Supplementary Table 5 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 5 includes baseline characteristics of individuals with cirrhosis eligible for HCC surveillance – private insurance only (N, %) (N=6,530).
Supplementary Table 2 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 2 includes the CPT/HCPCS codes for the HCC surveillance outcome definitions.
Supplementary Table 13 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 13 includes the two-year cumulative incidences for HCC surveillance overall and by insurance type, by calendar year of cirrhosis diagnosis, excluding individuals with decompensated cirrhosis (% and 95% confidence intervals).
Supplementary Table 11 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 11 includes the proportion of time covered measures for the entire cohort, by surveillance type and by payer.
Supplementary Table 10 from Hepatocellular Carcinoma Surveillance among Individuals with Cirrhosis: Trends by Payer, Etiology, and Calendar Year, from a Statewide, Multi-Payer Dataset, 2010–2018
Authors: Hsu Christine D. , Henderson Louise M. , Jackson Bradford E. , Baggett Christopher D. , Funk Michele Jonsson , Olshan Andrew F. , Gupta Parul , Barritt A. Sidney , Sanoff Hanna K. , Wheeler Stephanie B. , Moon Andrew M. , Lund Jennifer L.
Published: July 2023

Supplementary Table 10 includes two-year cumulative incidences by cirrhosis etiology and by insurance (% and 95% confidence intervals).
Supplementary Table 1 from Updated Review of Major Cancer Risk Factors and Screening Test use in the United States, with a Focus on Changes During the COVID-19 Pandemic
Authors: Star Jessica , Bandi Priti , Nargis Nigar , Islami Farhad , Yabroff K. Robin , Minihan Adair K. , Smith Robert A. , Jemal Ahmedin
Published: July 2023

Weighted population estimates of major cancer risk factors, preventive behaviors and services, and up-to-date cancer screening.
Table S6 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

Early-to-later-onset esophagogastric adenocarcinoma excess mortality rate ratios (EMRR) in patients diagnosed in years 2007-2019, exploring effect modification by sex (upper panel) and cancer stage (lower panel), with 95% confidence intervals (CI), model fit compared using the likelihood-ratio test (p-value).
Table S5 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

Sex distribution, numbers (n) and percentages (%) in early- (age 20-54 years) and later-onset (age 55-84 years) esophagogastric adenocarcinoma patients diagnosed in years 2007-2019.
Table S4 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

5-year relative survival in early- (age 20-49 years) and later-onset (age 50-84 years) esophagogastric adenocarcinoma diagnosed in years 2007-2019 together with early-to-later-onset excess mortality rate ratios (EMRR) with 95% confidence intervals (CI).
Table S2 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

Distribution, numbers (n) and percentages (%), of clinicopathological characteristics in early- (age 20-49 years) and later-onset (age 50-99 years) esophagogastric adenocarcinoma.
Figure S3 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

Early- (age 20-54 years, solid) and later-onset (age 55-99 years, dashed line) esophagogastric adenocarcinoma excess mortality rate (EMR) per 1,000 person-years over 5 years from diagnosis.
Figure S2 from Incidence Trends and Survival in Early-Onset Esophagogastric Adenocarcinoma: A Swedish Population-Based Cohort Study
Authors: Radkiewicz Cecilia , Asplund Johannes , Lagergren Jesper
Published: July 2023

Early- (age 20-54 years) and later-onset (55-99 years) esophagogastric adenocarcinoma incidence rate (IR) per 100,000 person-years over years 1993-2019, comparing empirical estimates (dots), modeled linear predictions with no breakpoint (blue solid line), together with linear predictions including one breakpoint year (red solid line) identified using piecewise linear regression.
Supplementary Table S4-S10 from Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies
Authors: Liu Zhiqiang , Zhang Yingfan , Lagergren Jesper , Li Shanshan , Li Jingru , Zhou Zhixian , Hu Zhijian , Xie Shao-Hua
Published: July 2023

Supplementary Table S4 shows associations with prediagnostic circulating sex hormones levels for esophageal cancer, Supplementary Table S5 for gastric cancer, Supplementary Table S6 for liver cancer, Supplementary Table S7 for pancreatic cancer, Supplementary Table S8 for colorectal cancer, Supplementary Table S9 for colon cancer, and Supplementary Table S10 shows associations for rectal cancer, all in subgroup analyses.
Supplementary Table 2 from Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide
Authors: Sedeta Ephrem , Sung Hyuna , Laversanne Mathieu , Bray Freddie , Jemal Ahmedin
Published: July 2023

Supplementary Table 2. Age-standardized mortality rate (ASR) per 100,000 person-years, 10-year average annual percent change (AAPC), and 5-year AAPC for 8 cancers by sex for 47 countries (bold font indicates statistically significant AAPC at p<0.05)
Supplementary Table S1 from Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies
Authors: Liu Zhiqiang , Zhang Yingfan , Lagergren Jesper , Li Shanshan , Li Jingru , Zhou Zhixian , Hu Zhijian , Xie Shao-Hua
Published: July 2023

Supplementary Table S1 shows characteristics of studies included in the meta-analysis.
Supplementary Table 1 from Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide
Authors: Sedeta Ephrem , Sung Hyuna , Laversanne Mathieu , Bray Freddie , Jemal Ahmedin
Published: July 2023

Supplementary Table 1. Country and time-period available for trend analysis of cancer mortality
Supplementary Figure 1 from Recent Mortality Patterns and Time Trends for the Major Cancers in 47 Countries Worldwide
Authors: Sedeta Ephrem , Sung Hyuna , Laversanne Mathieu , Bray Freddie , Jemal Ahmedin
Published: July 2023

Supplementary Figure 1. Age-standardized mortality rates per 100,000 person-years and ten-year average annual percent change in stomach cancer in males (A) and females (B) in 47 countries.
Supplementary Figure S5 from Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies
Authors: Liu Zhiqiang , Zhang Yingfan , Lagergren Jesper , Li Shanshan , Li Jingru , Zhou Zhixian , Hu Zhijian , Xie Shao-Hua
Published: July 2023

Supplementary Figure S5 shows forest plots (1), sensitivity analysis (2) and funnel plots (3) of the associations between prediagnostic circulating sex hormone levels and colorectal cancer risk.
Supplemental Table S5 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Stratified results for the association between residential position within a time zone and risk of colorectal cancer
Supplementary Figure S4 from Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies
Authors: Liu Zhiqiang , Zhang Yingfan , Lagergren Jesper , Li Shanshan , Li Jingru , Zhou Zhixian , Hu Zhijian , Xie Shao-Hua
Published: July 2023

Supplementary Figure S4 shows forest plots, sensitivity analysis and funnel plot of the associations between prediagnostic circulating sex hormone levels and pancreatic cancer risk.
Supplemental Table S4 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Stratified results for the association between chronotype and risk of colorectal cancer
Supplemental Table S2 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Characteristics of the night shift work analytic sample at the start of study follow-up according to categories of night shift work
Supplemental Table S1 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Characteristics of the residential position within a time zone analytic sample at study entry according to quartiles of residential position
Supplementary Figure S1 from Circulating Sex Hormone Levels and Risk of Gastrointestinal Cancer: Systematic Review and Meta-Analysis of Prospective Studies
Authors: Liu Zhiqiang , Zhang Yingfan , Lagergren Jesper , Li Shanshan , Li Jingru , Zhou Zhixian , Hu Zhijian , Xie Shao-Hua
Published: July 2023

Supplementary Figure S1 shows forest plots (1), sensitivity analysis (2) and funnel plots (3) of the associations between prediagnostic circulating sex hormone levels and esophageal cancer risk.
Supplemental Figure S3 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Flow diagram and timeline of BWHS participants included in the residential position within a time zone analysis
Supplemental Figure S1 from Circadian Disruption and Colorectal Cancer Incidence in Black Women
Authors: Barber Lauren E. , VoPham Trang , White Laura F. , Roy Hemant K. , Palmer Julie R. , Bertrand Kimberly A.
Published: July 2023

Flow diagram and timeline of BWHS participants included in the night shift work analysis
Supplementary Table S8 from Associations of Post-Diagnosis Lifestyle with Prognosis in Women with Invasive Breast Cancer
Authors: Troeschel Alyssa N. , Hartman Terryl J. , McCullough Lauren E. , Ergas Isaac J. , Collin Lindsay J. , Kwan Marilyn L. , Ambrosone Christine B. , Flanders W. Dana , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Wang Ying , Valice Emily , Kushi Lawrence H.
Published: July 2023

Hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of 2-year post-diagnosis lifestyle with all-cause mortality, breast cancer-mortality, and breast cancer recurrence among women diagnosed with stage I–III breast cancer.
Supplementary Table S4 from Associations of Post-Diagnosis Lifestyle with Prognosis in Women with Invasive Breast Cancer
Authors: Troeschel Alyssa N. , Hartman Terryl J. , McCullough Lauren E. , Ergas Isaac J. , Collin Lindsay J. , Kwan Marilyn L. , Ambrosone Christine B. , Flanders W. Dana , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Wang Ying , Valice Emily , Kushi Lawrence H.
Published: July 2023

Interactions Between the 2-Year Post-Diagnosis Lifestyle score and Selected Characteristics with All-Cause Mortality, Breast Cancer-Specific Mortality, and Breast Cancer Recurrence in the Pathways Study.
Supplementary Materials and Methods from Associations of Post-Diagnosis Lifestyle with Prognosis in Women with Invasive Breast Cancer
Authors: Troeschel Alyssa N. , Hartman Terryl J. , McCullough Lauren E. , Ergas Isaac J. , Collin Lindsay J. , Kwan Marilyn L. , Ambrosone Christine B. , Flanders W. Dana , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Wang Ying , Valice Emily , Kushi Lawrence H.
Published: July 2023

Supplementary text providing additional information regarding methods.
Supplementary Fig. S1 from Associations of Post-Diagnosis Lifestyle with Prognosis in Women with Invasive Breast Cancer
Authors: Troeschel Alyssa N. , Hartman Terryl J. , McCullough Lauren E. , Ergas Isaac J. , Collin Lindsay J. , Kwan Marilyn L. , Ambrosone Christine B. , Flanders W. Dana , Bradshaw Patrick T. , Cespedes Feliciano Elizabeth M. , Roh Janise M. , Wang Ying , Valice Emily , Kushi Lawrence H.
Published: July 2023

Cumulative incidence of all-cause mortality, breast cancer-specific mortality, and breast cancer recurrence among women diagnosed with invasive breast cancer in the Pathways Study, according to tertiles of the 2-year post-diagnosis lifestyle score, 2006–2018
Supplementary Fig. 2 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Authors: Antonarakis Emmanuel S. , Subudhi Sumit K. , Pieczonka Christopher M. , Karsh Lawrence I. , Quinn David I. , Hafron Jason M. , Wilfehrt Helen M. , Harmon Matthew , Sheikh Nadeem A. , Shore Neal D. , Petrylak Daniel P.
Published: July 2023

Supplementary Fig 2. Analysis of survival by baseline median alkaline phosphatase across the two studies using the study-specific median.
Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials
Authors: Antonarakis Emmanuel S. , Subudhi Sumit K. , Pieczonka Christopher M. , Karsh Lawrence I. , Quinn David I. , Hafron Jason M. , Wilfehrt Helen M. , Harmon Matthew , Sheikh Nadeem A. , Shore Neal D. , Petrylak Daniel P.
Published: July 2023

Supplementary Data for Antonarakis et al
Table S2 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy) , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: July 2023

Summary of BH3 profiling for PBMC samples collected at baseline.
Table S1 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy) , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: July 2023

Representativeness of study participants.
Supplementary Figures S1-S7 from Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial
Authors: Ailawadhi Sikander , Chen Zi , Huang Bo , Paulus Aneel , Collins Mary C. , Fu Lei (Tommy) , Li Mingyu , Ahmad Mohammad , Men Lichuang , Wang Hengbang , Davids Matthew S. , Liang Eric , Mekala Divya J. , He Zhicong , Lasica Masa , Yannakou Costas K. , Parrondo Ricardo , Glass Laura , Yang Dajun , Chanan-Khan Asher , Zhai Yifan
Published: July 2023

These are all the Supplementary Figures: S1, S2, S3, S4, S5, S6, and S7
Supplementary Figure S2 from Loss of CDKN2A Cooperates with WWTR1(TAZ)–CAMTA1 Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
Authors: Seavey Caleb N. , Hallett Andrea , Li Shuo , Che Kepeng , Pobbati Ajaybabu V. , Ma Shuang , Burtscher Ashley , Kanai Ryan , Lamar John M. , Rubin Brian P.
Published: July 2023

Ki67 staining and single-cell RNA sequencing
Supplementary Table 7 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Table 7. Baseline clinicopathologic features of patients with ATM mutated and ATM wild-type NSCLCs which underwent multiplexed immunofluorescence at the DFCI.
Supplementary Table 5 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Table 5. List of ATM mutations with matched IHC
Supplementary Table 4 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Table 4. Baseline clinicopathologic features of patients with ATM mutated NSCLC according ATM protein expression by immunohistochemistry.
Supplementary Figure S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
Authors: Doe-Tetteh Seyram A. , Camp Sabrina Y. , Reales Dalicia , Crowdis Jett , Noronha Anne Marie , Wolff Bernadette , Alano Tina , Galle Jesse , Selcuklu S. Duygu , Viale Agnes , Socci Nicholas D. , Liu Ying L. , Tew William P. , Aghajanian Carol , Ladanyi Marc , He Meng Xiao , AlDubayan Saud H. , Mazor Roei David , Shpilberg Ofer , Hershkovitz-Rokah Oshrat , Riancho Jose A. , Hernandez Jose L. , Gonzalez-Vela M. Carmen , Buthorn Justin J. , Wilson Manda , Webber Amy E. , Yabe Mariko , Petrova-Drus Kseniya , Rosenblum Marc , Durham Benjamin H. , Abdel-Wahab Omar , Berger Michael F. , Donoghue Mark T.A. , Kung Andrew L. , Glade Bender Julia , Shukla Neerav N. , Funt Samuel A. , Dogan Ahmet , Soslow Robert A. , Al-Ahmadie Hikmat , Feldman Darren R. , Van Allen Eliezer M. , Diamond Eli L. , Solit David B.
Published: July 2023

Clonality assessment of known oncogenic mutations in the female GCT cohort.
Supplementary Table 2 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Table 2. List of potential ATM germline variants identified among 3800 patients with NSCLC at the DFCI
Supplementary Figure 9 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 9. (A) Disease free- and overall survival among patients with (A) stage I, and (B) stage II NSCLC according to ATM mutation status.
Supplementary Figure 8 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 8. Oncoprint plot showing the distribution of the most commonly mutated genes in NSCLCs with complete ATM loss by IHC (ATMLOST), intact ATM expression (ATMINTACT), and ATM heterogeneous loss (ATMHET LOST) by IHC.
Supplementary Figure 4. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 4. (A) Volcano plot showing gene mutations significantly enriched among NSCLCs harboring ATM missense mutations that were predicted to benign in silico versus NSCLCs without any ATM mutation. (B) Volcano plot showing gene mutations significantly enriched among ATMWT and ATMMUT samples in the TCGA-NSCLC cohort.
Supplementary Figure 29 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 29. Box plot showing immune cell subsets significantly enriched among ATMMUT versus ATMWT NSCLC as assessed by deconvoluting bulky RNAseq data from the TCGA-NSCLC dataset. Non-significant results are not shown.
Supplementary Figure 27 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 27. Tumor mutational burden in NSCLC samples which underwent NGS at the DFCI and MSK according to ATM/TP53 co-mutation status.
Supplementary Figure 26 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 26. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells according to ATM/TP53 co-mutation status.
Supplementary Figure 24 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 24. (A) Intratumoral, (B) tumor-stroma interface, and (C) total CD8+ T cells according to ATM/TP53 co-mutation status. (D) Intratumoral, (E) tumor-stroma interface, and (F) total PD1+ immune cells according to ATM/TP53 co-mutation status.
Supplementary Figure 23. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 23. Correlation of intratumoral, tumor-stroma interface, and total CD8+, PD1+, CD8+PD1+, FOXP3+ T cells and tumoral and non-tumoral PD-L1+ cells among ATMMUT NSCLCs.
Supplementary Figure 22. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 22. Proportion of (A) tumor, (B) non-tumor, and (C) total PD-L1+ cells in ATMMUT and ATMWT NSCLCs.
Supplementary Figure 19 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 19. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 immune checkpoint blockade monotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with ATMMUT NSCLC, according to KEAP1 mutation status
Supplementary Figure 17 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 17. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to PD-(L)1 inhibition among patients with advanced/metastatic NSCLC, according to ATM expression by immunohistochemistry.
Supplementary Figure 15 from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 15. (A) Objective response rate, (B) progression-free survival, and (C) overall survival to chemo-immunotherapy among patients with advanced/metastatic PD-L1 negative (<1%) NSCLC, according to ATM mutation status. (D) Objective response rate, (E) progression-free survival, and (F) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 intermediate (1-49%) NSCLC, according to ATM mutation status. (G) Objective response rate, (H) progression-free survival, and (I) overall survival to PD-(L)1 immune checkpoint blockade in combination with platinum doublet chemotherapy among patients with advanced/metastatic PD-L1 high (≥50%) NSCLC, according to ATM mutation status.
Supplementary Data File 1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand , Madhusudanannair-Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: July 2023

Exosome Analysis Summary
Supplemental Table S3 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand , Madhusudanannair-Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: July 2023

Exosome (50-120nm N=24) PFS Analysis Proportional Hazard Model with Adjustment for Study Arm
Supplementary Figure 1. from Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non–Small Cell Lung Cancer
Authors: Ricciuti Biagio , Elkrief Arielle , Alessi Joao , Wang Xinan , Li Yvonne , Gupta Hersh , Muldoon Daniel M. , Bertram Arrien A. , Pecci Federica , Lamberti Giuseppe , Di Federico Alessandro , Barrichello Adriana , Vaz Victor R. , Gandhi Malini , Lee Elinton , Shapiro Geoffrey I. , Park Hyesun , Nishino Mizuki , Lindsay James , Felt Kristen D. , Sharma Bijaya , Cherniack Andrew D. , Rodig Scott , Gomez Daniel R. , Shaverdian Narek , Rakaee Mehrdad , Bandlamudi Chaitanya , Ladanyi Marc , Janne Pasi A. , Schoenfeld Adam J. , Sholl Lynette M. , Awad Mark M. , Cheng Michael L.
Published: July 2023

Supplementary Figure 1. (A) ATM mutation classification schema (B) Lollipop plot of all 714 mutations in the ATM gene identified in the combined DFCI/MSK cohort. (C) Lollipop plot of all 152 benign mutations in the ATM gene identified in the combined DFCI/MSK cohort.
Supplemental Figure S1 from Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma
Authors: Kelly William , Diaz Duque Adolfo Enrique , Michalek Joel , Konkel Brandon , Caflisch Laura , Chen Yidong , Pathuri Sarath Chand , Madhusudanannair-Kunnuparampil Vinu , Floyd John , Brenner Andrew
Published: July 2023

CONSORT flow diagram with patient disposition and treatment
Supplementary Table S2 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Authors: Luke Jason J. , Piha-Paul Sarina A. , Medina Theresa , Verschraegen Claire F. , Varterasian Mary , Brennan Aoife M. , Riese Richard J. , Sokolovska Anna , Strauss James , Hava David L. , Janku Filip
Published: July 2023

Supplemental Table 2. Tumor types and characteristics for Nanostring and immunofluorescence data analysis